Ascletis was established in 2013 and has been listed on the Hong Kong Stock Exchange since 2018 (1672.HK). Ascletis focuses on the R&D and commercialization of novel medicines in non-alcoholic steatohepatitis (NASH), cancer lipid metabolism, oral checkpoint inhibitors, viral hepatitis and HIV/AIDS to meet unmet medical needs on a global basis. Gannex, a wholly-owned company of Ascletis, is dedicated to the R&D and commercialization of new drugs in the field of NASH. 

We are looking forward to partnering with academia, biotech and pharmaceutical companies around the world to jointly discover and develop truly innovative NASH medicines for patients on a global basis! If you would like to know more information on partnering with Gannex, please contact our business development team through

  • Sagimet is a clinical-stage biopharmaceutical company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of several diseases that result from the overproduction of the fatty acid palmitate. For more information, please visit

  • Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase III registrational study.